CPRX News and Press, Catalyst Pharmaceuticals Inc. From 06/28/21

Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $6.17. This new high was reached on below average trading volume as 301,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Catalyst Pharmaceuticals Inc. ...

Catalyst Pharmaceuticals (CPRX) has entered into an exclusive license and supply agreement with DyDo Pharma for the development and commercialization of Firdapse (amifampridine) Tablets 10 mg in Japan for the treatment of Lambert-Eaton myasthenic syndrome ((LEMS)).LEMS is a rare autoimmune ne...

CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...

- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla., June 03,...

Catalyst has registered solid performance over the past quarter and previous two years. Aside from its BioMarin deals, Catalyst's efforts to expand its pipeline have met with little success. Catalyst's pricing for Firdapse has generated controversy and competition. Catalyst is...

Catalyst Pharmaceuticals is a small cap biopharma company with a highly profitable ultra-orphan drug, Firdapse, for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS). Firdapse was the subject of a pricing controversy. Subsequently, FDA granted off-label approval ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.69. This new high was reached on below average trading volume as 109,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. In the past 52 weeks, Catalyst Pharmaceu...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.81. Approximately 109,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. share prices have moved between a 52-week high of $...

Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.61. This new high was reached on below average trading volume as 109,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. Catalyst Pharmaceuticals Inc. ...

CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare dise...